Open the map

Eli LillyLLY

Diabetes & metabolic disease · NYSE · USA

$1,169.60
Down 1.6% todayClose

Up 10.6% this year but −3.2% since June 26, behind the life science sector at +10.7%. Eli Lilly supplies 3 mapped companies and buys from 6.

Market cap
$1.1T
This year
+10.6%
1 year
+40.9%
P/E
41.0
P/S
13.8
P/B
32.3

Price vs the life science sector

since Jun 26LLYLife science sector, equal weight
Eli Lilly (LLY) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. LLY: −3.2% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−5%0%+5%+10%+15%Jun 26AugSepOct 8LLY −3.2%Sector +10.7% Eli Lilly (LLY) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. LLY: −3.2% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%Jun 26AugSepOct 8LLY−3.2%Sector+10.7%

Supply chain

6 suppliers · 3 customers
SUPPLIERS →→ CUSTOMERSThermo Fisher Scientific (TMO)TMOThermo Fisher Scien…−1.5%West Pharmaceutical Services (WST)WSTWest Pharmaceutical…−0.9%Charles River Laboratories (CRL)CRLCharles River Labor…−0.8%Waters Corporation (WAT)WATWaters Corporation−1.6%IQVIA Holdings (IQV)IQVIQVIA Holdings+0.3%Danaher (DHR)DHRDanaher−0.5%Cardinal Health (CAH)CAHCardinal Health+2.9%McKesson (MCK)MCKMcKesson+2.2%Cencora (COR)CORCencora+1.3%LLYEli Lilly

Suppliers 6

Customers 3

Open the full chain →

About Eli Lilly

Mounjaro and Zepbound put Lilly at the centre of the GLP-1 market. Around them sit the diabetes and insulin business and franchises in oncology and neurology, with a pipeline that ranks among the strongest in the industry.

Theme exposure

GLP-1ObesityDiabetes exposureDiabetes

Products

  • GLP-1 (Mounjaro, Zepbound)
  • Diabetes & insulin
  • Oncology & neurology

Competitors

Risks

  • High valuation
  • Manufacturing capacity
  • Patent cliff over time

Same segment: Diabetes & metabolic disease

Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring. Segment 1 of 8 in the Medicine, pharma & life science value chain.

DexComDXCM+0.1%InsuletPODD+0.1%

Compare LLY

Side by side with the largest companies in the same segment.

LLY vs DXCMLLY vs PODD

See where Eli Lilly sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →